RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak
RedHill Biopharma is actively discussing collaborations to advance its investigational drug opaganib for the treatment of Ebola virus disease (EVD), including potential inclusion in the WHO's SOLIDARITY CORE clinical trial platform. The company cites existing Phase 3 data from severe COVID-19 trials showing a 70.2% mortality reduction with opaganib as an add-on therapy, alongside preclinical USAMRIID-funded studies demonstrating opaganib's inhibition of EVD in human macrophages and increased survival in animal models.
Key figures
- Drug Name
- opaganib
- Phase Of Trial
- Phase 3 (for severe COVID-19; preclinical for EVD)
- Clinical participants
- 470
- Covid mortality reduction
- 70.2%
- Covid placebo mortality rate
- 23.4%
- Covid opaganib mortality rate
- 6.98%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.